36 completed, 4 unknown, 3 withdrawn, 2 terminated. 47 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 47 | Completed 36, Unknown 4, Withdrawn 3, Terminated 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Vortioxetine: new trials by email Literature Review of Vortioxetine trials Research Report on Vortioxetine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder KH607 tablets, Vortioxetine Hydrobromide Tablets, Part B: KH607 - Major Depressive Disorder (MDD) | Phase 3 | Not yet recruiting | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 326 | 2026-07-01 | 2026-08-03 |
| A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder Vortioxetine tablets, Placebo tablets - Major Depressive Disorder | Phase 3 | Recruiting | Takeda | 180 | 2025-10-01 | 2026-10-29 |
| Postoperative Pain Management Following Laparoscopic Cholecystectomy Vortioxetine 20Mg Tab - Postoperative Pain | Phase 3 | Completed | Future University in Egypt | 86 | 2024-08-26 | 2026-09-21 |
| Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome Vortioxetine 20Mg Tab, Paroxetine 20 Mg Oral Tablet, Sertraline 50 MG - Burning Mouth Syndrome | Phase 3 | Unknown | Federico II University | 203 | 2023-01-01 | 2023-09-06 |
| Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities Vortioxetine, Venlafaxine - Major Depressive Disorder | Phase 3 | Unknown | Scotmann Pharmaceuticals | 500 | 2022-02-01 | 2021-11-18 |
| Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia Vortioxetine, Usual Antipsychotic Treatment - Cognitive Impairment With Primary Psychotic Disorder, Negative Symptoms With Primary Psychotic Disorder | Phase 2 / Phase 3 | Unknown | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 37 | 2022-01-20 | 2024-02-26 |
| Vortioxetine to Prevent Return of Symptoms in Children With Depression Vortioxetine, Placebo - Depression | Phase 3 | Terminated | H. Lundbeck A/S | 35 | 2021-08-10 | 2023-01-05 |
| Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy Vortioxetine 10 mg, Placebo - Radiation Injuries | Phase 3 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 208 | 2020-10-10 | 2021-03-26 |
| Vortioxetine for the Treatment of Hoarding Disorder Vortioxetine Tablets - Hoarding Disorder | Phase 3 | Withdrawn | Noam Soreni | 2019-08-01 | 2024-02-02 | |
| Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) Rapastinel, Vortioxetine, Placebo - Depressive Disorder, Major | Phase 3 | Withdrawn | Naurex, Inc, an affiliate of Allergan plc | 2019-07-01 | 2019-07-19 | |
| Substance Misuse To Psychiatric Disorders for Cannabis Vortioxetine, Treatment as Usual - Cannabis Use Disorder, Depressive State | Phase 2 / Phase 3 | Completed | The University of Hong Kong | 37 | 2018-07-25 | 2023-07-05 |
| THINC-it Vortioxetine - Sensitivity to Change Vortioxetine, THINC-it Tool - Major Depressive Disorder, Cognitive Change | Phase 2 / Phase 3 | Completed | Brain and Cognition Discovery Foundation | 158 | 2017-05-24 | 2025-06-08 |
| Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age Vortioxetine - Depressive Disorder, Major | Phase 3 | Completed | H. Lundbeck A/S | 94 | 2017-03-01 | 2021-06-24 |
| Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI) Vortioxetine, Placebo - TBI, Major Depression | Phase 3 | Withdrawn | Johns Hopkins University | 2016-10-01 | 2016-09-02 | |
| Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age Vortioxetine - Depressive Disorder, Major | Phase 3 | Terminated | H. Lundbeck A/S | 662 | 2016-08-17 | 2022-12-28 |
| Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day - Depressive Disorder, Major | Phase 3 | Completed | H. Lundbeck A/S | 683 | 2016-05-18 | 2022-09-22 |
| Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day - Depressive Disorder, Major | Phase 3 | Completed | H. Lundbeck A/S | 784 | 2016-05-01 | 2020-08-19 |
| A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder Placebo, Vortioxetine - Major Depressive Disorder | Phase 3 | Completed | Takeda | 493 | 2015-04-10 | 2021-03-24 |
| Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder Vortioxetine 10-20 mg, Escitalopram 10-20 mg - Major Depressive Disorder | Phase 3 | Completed | H. Lundbeck A/S | 101 | 2014-12-01 | 2017-02-28 |
| Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder Vortioxetine 10 mg, Paroxetine 20 mg, Placebo - Major Depressive Disorder | Phase 3 | Completed | H. Lundbeck A/S | 152 | 2014-10-01 | 2017-02-28 |
Showing 20 of 47. Sign in to see all of them.
Depressive Disorder, Major (35) · Depression (16) · Depressive Disorder (7) · Mood Disorders (6) · Anxiety Disorders (5) · Generalized Anxiety Disorder (5) · Mental Disorders (2) · Behavioral Symptoms (1) · Burning Mouth Syndrome (1) · Cognitive Dysfunction (1) · Dysthymic Disorder (1) · Head and Neck Neoplasms (1) · Hoarding Disorder (1) · Marijuana Abuse (1) · Pain, Postoperative (1)
H. Lundbeck A/S (18) · Takeda (18) · Brain and Cognition Discovery Foundation (1) · Chengdu Kanghong Pharmaceutical Group Co., Ltd. (1) · Federico II University (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Future University in Egypt (1) · Johns Hopkins University (1) · Naurex, Inc, an affiliate of Allergan plc (1) · Noam Soreni (1) · Scotmann Pharmaceuticals (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · The University of Hong Kong (1)
United States (14) · Germany (11) · Russia (10) · Latvia (9) · Poland (9) · Estonia (8) · Serbia (8) · Ukraine (8) · Canada (7) · France (7) · South Africa (7) · South Korea (6) · Colombia (5) · Finland (5) · Hungary (5)
Albert KK Chung, MBBS(HK) (1) · Benedicto Crespo Facorro, Professor (1) · Marc Debelle (1) · Muhammad Umar (1) · Noam Soreni, MD (1) · Roger McIntyre (1)
PMID 27780334, PMID 31818787, PMID 36708956, PMID 29081307, PMID 29160598, PMID 30439678, PMID 31087825, PMID 32242018, PMID 22209361, PMID 22475889, PMID 22495621, PMID 22572889, PMID 22898365, PMID 22901736, PMID 22963932, PMID 22978748, PMID 23252878, PMID 24257717, PMID 24341301, PMID 24424707, PMID 24787143, PMID 25087600, PMID 25575488, PMID 25650503, PMID 26035185, PMID 26035186, PMID 28858412, PMID 29554497, PMID 30766492, PMID 31010445, PMID 31404802, PMID 31990207, PMID 32670103, PMID 33833401, PMID 34955641, PMID 34992372, PMID 35033635, PMID 35221687, PMID 36884024, PMID 40016875, PMID 40922774
2008 (8), 2014 (3), 2009 (1), 2015 (1), 2018 (1)